10-Q quarterly report · filed Nov 3, 2026

Stoke Therapeutics, Inc. (STOK) Q3 2026 10-Q Quarterly Report

Short answer

Stoke Therapeutics, Inc. (STOK) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $11M (up 5.9% year over year) with net income of −$74M.

Q3 2026 key financials · XBRL

Revenue
$11M
+5.9% YoY · +20.7% QoQ
Net income
−$74M
−92.0% YoY · −19.5% QoQ
Operating margin
-687.0%
EPS (diluted)
−$1.08
−66.2% YoY · −14.9% QoQ

Source: XBRL data from the Stoke Therapeutics, Inc. (STOK) Q3 2026 10-Q on SEC EDGAR. USD.

Stoke Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $11.3M, up $0.7M YoY from $10.6M, driven by Acadia and Biogen collaborations
  • Operating margin (77,315 ÷ 11,255) not disclosed as a percentage, versus (43,091 ÷ 10,632) not disclosed
  • Best-performing program: zorevunersen R&D $28.7M vs $19.0M; ADOA $3.6M vs $1.6M
  • Cash, equivalents and marketable securities $358.8M vs $390.9M at December 31, 2025; operations funded into early 2028
  • Operating cash flow $(179.9)M vs $76.0M; financing provided $156.4M, including $146.4M from equity offering

Risk Factors

  • Newly added regulatory risk: FDA staffing reductions and funding constraints could delay reviews, guidance and approvals under the current administration
  • Most materially updated pricing risk: finalized 2026 GLOBE Model begins January 1, 2027, potentially reducing Medicare Part B drug prices
  • Clinical risk: STK-002 entered its OSPREY Phase 1 study after first-patient dosing in February 2026
  • Near-term operational risk: EMPEROR Phase 3 execution depends on hospital staffing and patient enrollment, despite first dosing in August 2025
  • Liquidity risk: $358.8 million cash, equivalents and marketable securities expected to fund operations into early 2028

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Stoke Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.